BG106103A - Estrogen receptor-beta-ligands - Google Patents
Estrogen receptor-beta-ligandsInfo
- Publication number
- BG106103A BG106103A BG106103A BG10610301A BG106103A BG 106103 A BG106103 A BG 106103A BG 106103 A BG106103 A BG 106103A BG 10610301 A BG10610301 A BG 10610301A BG 106103 A BG106103 A BG 106103A
- Authority
- BG
- Bulgaria
- Prior art keywords
- beta
- estrogen receptor
- ligands
- kibetae
- kibetaa
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12990199P | 1999-04-16 | 1999-04-16 | |
PCT/GB2000/001380 WO2000062765A2 (en) | 1999-04-16 | 2000-04-11 | ESTROGEN RECEPTOR-β LIGANDS |
Publications (1)
Publication Number | Publication Date |
---|---|
BG106103A true BG106103A (en) | 2002-05-31 |
Family
ID=22442124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG106103A BG106103A (en) | 1999-04-16 | 2001-11-13 | Estrogen receptor-beta-ligands |
Country Status (22)
Country | Link |
---|---|
US (1) | US6518301B1 (xx) |
EP (1) | EP1173164A2 (xx) |
JP (1) | JP2002542187A (xx) |
KR (1) | KR20010108509A (xx) |
CN (1) | CN1358091A (xx) |
AR (1) | AR043085A1 (xx) |
AU (1) | AU4128800A (xx) |
BG (1) | BG106103A (xx) |
BR (1) | BR0009814A (xx) |
CA (1) | CA2370126A1 (xx) |
CZ (1) | CZ20013714A3 (xx) |
EE (1) | EE200100526A (xx) |
HU (1) | HUP0200740A3 (xx) |
IL (1) | IL145839A0 (xx) |
IS (1) | IS6108A (xx) |
MX (1) | MXPA01010423A (xx) |
NO (1) | NO20015015L (xx) |
PL (1) | PL351314A1 (xx) |
SK (1) | SK14762001A3 (xx) |
TR (2) | TR200201762T2 (xx) |
WO (1) | WO2000062765A2 (xx) |
ZA (1) | ZA200108409B (xx) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ266199A0 (en) * | 1999-09-06 | 1999-09-30 | Novogen Research Pty Ltd | Compositions and therapeutic methods involving isoflavones and analogues thereof |
US7226945B2 (en) | 2000-10-13 | 2007-06-05 | Astrazeneca Ab | Estrogen receptor-β ligands |
GB2361642A (en) * | 2000-10-24 | 2001-10-31 | Karobio Ab | Estrogen receptor beta (ERbeta) agonists for use in cancer treatment |
WO2002046164A1 (en) * | 2000-12-07 | 2002-06-13 | Astrazeneca Ab | Therapeutic compounds |
WO2002046168A1 (en) * | 2000-12-07 | 2002-06-13 | Astrazeneca Ab | Therapeutic benzimidazole compounds |
US6559177B2 (en) | 2001-04-19 | 2003-05-06 | Wyeth | 5, 11-Dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents |
IL161325A0 (en) | 2001-11-19 | 2004-09-27 | Lilly Co Eli | Substituted benzopyrans as selective estrogen receptor-beta agonists |
UA83620C2 (ru) | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
US6914074B2 (en) * | 2001-12-13 | 2005-07-05 | Wyeth | Substituted phenyl naphthalenes as estrogenic agents |
TW200301107A (en) | 2001-12-13 | 2003-07-01 | Wyeth Corp | Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents |
US6835745B2 (en) | 2002-01-15 | 2004-12-28 | Wyeth | Phenyl substituted thiophenes as estrogenic agents |
US7235539B2 (en) | 2002-01-23 | 2007-06-26 | Wyeth | 6-Hydroxyequilenins as estrogenic agents |
AU2003212856A1 (en) * | 2002-03-01 | 2003-09-16 | Eli Lilly And Company | Substituted benzopyrans as selective estrogen receptor-beta agonists |
EP1545206B1 (en) | 2002-07-24 | 2020-03-04 | Children's Hospital Medical Center | Compositions and products containing enantiomeric equol, and methods for their making |
US8668914B2 (en) | 2002-07-24 | 2014-03-11 | Brigham Young University | Use of equol for treating skin diseases |
WO2004039327A2 (en) | 2002-10-29 | 2004-05-13 | Colorado State University Research Foundation | Use of equol for treating androgen mediated diseases |
US7468445B2 (en) | 2002-08-07 | 2008-12-23 | University Of Mississippi | Antigiardial agents and use thereof |
US8580846B2 (en) | 2002-10-29 | 2013-11-12 | Brigham Young University | Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders |
US7674783B2 (en) * | 2002-11-22 | 2010-03-09 | Dimera Inc. | Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease |
DE602004016150D1 (de) * | 2003-04-21 | 2008-10-09 | Lilly Co Eli | Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta |
EP2305272A1 (en) * | 2004-04-28 | 2011-04-06 | Brigham Young University | Use of equol for treating skin diseases |
PE20060503A1 (es) * | 2004-08-26 | 2006-07-20 | Wyeth Corp | Prodroga de benzoxazoles substituidos como agentes estrogenicos |
EP1789420A2 (en) | 2004-09-07 | 2007-05-30 | Wyeth, A Corporation of the State of Delaware | 6H-[1]BENZOPYRANO[4,3-b]QUINOLINES AND THEIR USE AS ESTROGENIC AGENTS |
US20060135574A1 (en) * | 2004-12-17 | 2006-06-22 | Wyeth | Novel uses for estrogen beta agonists |
WO2006088716A1 (en) * | 2005-02-15 | 2006-08-24 | Eli Lilly And Company | Substituted tetralins as selective estrogen receptor-beta agonists |
CN101203219B (zh) * | 2005-03-24 | 2011-06-15 | 诺沃根研究控股有限公司 | 消炎用药程式 |
US8546451B2 (en) * | 2005-11-28 | 2013-10-01 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
US9409856B2 (en) | 2005-11-28 | 2016-08-09 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
EA201500845A1 (ru) * | 2005-11-28 | 2016-04-29 | Джи Ти Икс, ИНК. | Агенты, связывающиеся с ядерными рецепторами |
US8158828B2 (en) * | 2005-11-28 | 2012-04-17 | Gtx, Inc. | Nuclear receptor binding agents |
US8637706B2 (en) | 2005-11-28 | 2014-01-28 | Gtx, Inc. | Nuclear receptor binding agents |
TWI366565B (en) | 2007-06-06 | 2012-06-21 | Otsuka Pharma Co Ltd | Quinolone compound and pharmaceutical composition |
WO2009026657A1 (en) * | 2007-08-29 | 2009-03-05 | The University Of Sydney | Flavonoid ppar agonists |
US8592007B2 (en) * | 2008-10-29 | 2013-11-26 | Merck Patent Gmbh | Liquid-crystal display |
TWI492943B (zh) | 2008-12-05 | 2015-07-21 | 大塚製藥股份有限公司 | 喹啉酮化合物及藥學組成物(二) |
ES2343347B2 (es) * | 2009-01-27 | 2011-12-07 | Universidade De Santiago De Compostela | Uso de derivados de 3-fenilcumarinas 6-sustituidas y preparacion de nuevos derivados. |
US9624161B2 (en) | 2009-02-23 | 2017-04-18 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
US9427418B2 (en) | 2009-02-23 | 2016-08-30 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
CN101863867B (zh) * | 2009-04-14 | 2012-07-18 | 清华大学深圳研究生院 | 黄酮类化合物的衍生物及其制备方法与应用 |
WO2012147102A1 (en) * | 2011-04-25 | 2012-11-01 | Council Of Scientific & Industrial Research | Bioactive fractions and compounds from dalbergia sissoo for the prevention or treatment of osteo-health related disorders |
CN103450134B (zh) * | 2012-05-31 | 2017-12-22 | 中国医学科学院药物研究所 | 香豆素衍生物的制备及其在防治脑部重大疾病中的应用 |
US9718799B2 (en) * | 2015-05-11 | 2017-08-01 | University Of Kentucky Research Foundation | 3-aryl-4H-chromene-4-ones as antineoplastic agents for the treatment of cancer |
EP3597187A1 (en) * | 2018-07-16 | 2020-01-22 | Centre National De La Recherche Scientifique | Brag2 inhibitors and applications thereof |
CN112574177B (zh) * | 2020-12-21 | 2023-01-31 | 陕西师范大学 | 一类嘧啶衍生物及其制备抗肿瘤药物的应用 |
CN115322198A (zh) * | 2022-06-13 | 2022-11-11 | 上海工程技术大学 | 基于喹诺里西啶类衍生物的药物化合物及其制备方法和应用 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4954371A (xx) * | 1972-09-28 | 1974-05-27 | ||
GB1495189A (en) * | 1975-09-12 | 1977-12-14 | Pfizer Ltd | 4-oxo-4h-benzopyran derivatives and process for their preparation |
JPS6048924A (ja) | 1983-08-24 | 1985-03-16 | Takeda Chem Ind Ltd | 骨粗鬆症治療剤 |
ZA873745B (en) * | 1986-06-04 | 1988-10-26 | Daiichi Seiyaku Co | Benzopyran derivatives |
JP3085464B2 (ja) * | 1990-05-24 | 2000-09-11 | コニカ株式会社 | 感熱拡散転写材料 |
US5204369A (en) * | 1991-07-01 | 1993-04-20 | The Endowment For Research In Human Biology | Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse |
JPH05112552A (ja) * | 1991-10-17 | 1993-05-07 | Tanabe Seiyaku Co Ltd | ベンゾピラン誘導体及びその製法 |
JP3166093B2 (ja) * | 1993-08-13 | 2001-05-14 | 森永乳業株式会社 | クマリン誘導体及びそれらの用途 |
JPH06321752A (ja) * | 1993-05-07 | 1994-11-22 | Kao Corp | 美白剤 |
JP3522754B2 (ja) * | 1993-12-16 | 2004-04-26 | マリンクロッド・インコーポレイテッド | 多価フェノール化合物類 |
US5998401A (en) * | 1995-02-28 | 1999-12-07 | Eli Lilly And Company | Naphthyl compounds, intermediates, compositions, and methods |
JP3786447B2 (ja) * | 1995-03-31 | 2006-06-14 | エーザイ株式会社 | C型肝炎の予防・治療剤 |
AUPO203996A0 (en) * | 1996-08-30 | 1996-09-26 | Novogen Research Pty Ltd | Therapeutic uses |
US5916916A (en) * | 1996-10-10 | 1999-06-29 | Eli Lilly And Company | 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods |
US5733926A (en) * | 1996-12-13 | 1998-03-31 | Gorbach; Sherwood L. | Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions |
GB9707013D0 (en) * | 1997-04-07 | 1997-05-28 | Univ Strathclyde | Halo and/or nitro-substituted flavonoids |
CA2287965C (en) * | 1997-05-01 | 2009-10-20 | Graham Edmund Kelly | Treatment or prevention of menopausal symptoms and osteoporosis |
-
2000
- 2000-04-11 CZ CZ20013714A patent/CZ20013714A3/cs unknown
- 2000-04-11 HU HU0200740A patent/HUP0200740A3/hu unknown
- 2000-04-11 SK SK1476-2001A patent/SK14762001A3/sk unknown
- 2000-04-11 CN CN00809003A patent/CN1358091A/zh active Pending
- 2000-04-11 AU AU41288/00A patent/AU4128800A/en not_active Abandoned
- 2000-04-11 US US09/959,032 patent/US6518301B1/en not_active Expired - Fee Related
- 2000-04-11 TR TR2002/01762T patent/TR200201762T2/xx unknown
- 2000-04-11 PL PL00351314A patent/PL351314A1/xx not_active Application Discontinuation
- 2000-04-11 EP EP00920872A patent/EP1173164A2/en not_active Withdrawn
- 2000-04-11 JP JP2000611902A patent/JP2002542187A/ja active Pending
- 2000-04-11 WO PCT/GB2000/001380 patent/WO2000062765A2/en not_active Application Discontinuation
- 2000-04-11 EE EEP200100526A patent/EE200100526A/xx unknown
- 2000-04-11 CA CA002370126A patent/CA2370126A1/en not_active Abandoned
- 2000-04-11 BR BR0009814-0A patent/BR0009814A/pt not_active IP Right Cessation
- 2000-04-11 TR TR2001/02992T patent/TR200102992T2/xx unknown
- 2000-04-11 KR KR1020017013143A patent/KR20010108509A/ko not_active Application Discontinuation
- 2000-04-11 MX MXPA01010423A patent/MXPA01010423A/es unknown
- 2000-04-11 IL IL14583900A patent/IL145839A0/xx unknown
- 2000-04-14 AR ARP000101771A patent/AR043085A1/es unknown
-
2001
- 2001-10-12 ZA ZA200108409A patent/ZA200108409B/xx unknown
- 2001-10-15 IS IS6108A patent/IS6108A/is unknown
- 2001-10-15 NO NO20015015A patent/NO20015015L/no not_active Application Discontinuation
- 2001-11-13 BG BG106103A patent/BG106103A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
HUP0200740A3 (en) | 2004-08-30 |
KR20010108509A (ko) | 2001-12-07 |
JP2002542187A (ja) | 2002-12-10 |
AU4128800A (en) | 2000-11-02 |
IL145839A0 (en) | 2002-07-25 |
HUP0200740A2 (hu) | 2002-07-29 |
AR043085A1 (es) | 2005-07-20 |
SK14762001A3 (sk) | 2002-10-08 |
CZ20013714A3 (cs) | 2002-08-14 |
CA2370126A1 (en) | 2000-10-26 |
EP1173164A2 (en) | 2002-01-23 |
IS6108A (is) | 2001-10-15 |
PL351314A1 (en) | 2003-04-07 |
NO20015015L (no) | 2001-12-17 |
US6518301B1 (en) | 2003-02-11 |
BR0009814A (pt) | 2002-01-08 |
NO20015015D0 (no) | 2001-10-15 |
TR200102992T2 (tr) | 2004-12-21 |
MXPA01010423A (es) | 2002-03-27 |
EE200100526A (et) | 2002-12-16 |
CN1358091A (zh) | 2002-07-10 |
ZA200108409B (en) | 2003-03-26 |
WO2000062765A2 (en) | 2000-10-26 |
TR200201762T2 (tr) | 2002-10-21 |
WO2000062765A3 (en) | 2001-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG106103A (en) | Estrogen receptor-beta-ligands | |
BG104056A (en) | Triazole compounds and their use as dopamine-d3-ligands | |
EP0931788A3 (en) | Metalloprotease inhibitors | |
BG105784A (en) | Triazole compounds with dopamine-d3-receptor affinity | |
CA2301189A1 (en) | Non-steroidal ligands for the estrogen receptor | |
AU7278500A (en) | Fungicides | |
AU2002224893A1 (en) | Method for producing a part and device for carrying out this method | |
HUP0100221A3 (en) | Sustained release compositions, process for producing the same and utilization thereof | |
TR200102800T2 (tr) | Yeni bileşikler. | |
ZA200005369B (en) | Calcilytic compounds. | |
HK1039454A1 (en) | Remedies for hypercalcemic crisis. | |
AP2001002220A0 (en) | Calcilytic compounds. | |
BG104291A (en) | 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use | |
IN187760B (xx) | ||
BG106002A (en) | Process for preparing pesticidal intermediates | |
EP0899255A3 (en) | Fungicidal 2,6,6'-trimethylbenzophenones | |
HK1039620A1 (en) | High purity compound (7alpha, 17alpha)-17-hydroxyl-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one | |
MX9804659A (es) | Tiazolinas substituidas y su empleo para la lucha contra las pestes animales. | |
PL345204A1 (en) | Compounds with growth hormone releasing properties | |
NZ513453A (en) | Resorcinol composition | |
ZA200005540B (en) | New hydroxyindoles, their use as phosphodiestrase 4 inhibitors and method for producing same. | |
MXPA03002926A (es) | Proceso para la sintesis de 2,2,6,6,-tetrametil-4--oxipiperidina. | |
CZ20022240A3 (cs) | Mannichovy báze substituovaného 1-a 2-naftolu | |
RU98116380A (ru) | Применение ингибиторов натрий-водородного обмена для получения лекарственного средства в целях лечения заболеваний, вызываемых простейшими | |
AU2356501A (en) | Bis-basic compounds for use as tryptase inhibitors, method for producing the same and their use as medicaments |